Teresa Moran

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.

TL;DR: In this paper, the authors evaluated response patterns among EGFR-mutant, ALK-positive, and EGFR wild-type/ALK-negative patients and identified 58 patients treated with PD-1/PD-L1 inhibitors.

TL;DR: Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC.

TL;DR: Crystal structure and detailed analysis of different EGFR mutants explain why some mutations in exon 20 make lung cancers resistant to EGFR inhibitors and others make them more sensitive to TKIs, and how to design drugs that exploit the unique structural features of resistant mutants and specifically target them for treatment.